

# Market Announcement

22 July 2020

---

## Invex Therapeutics Limited (ASX: IXC) – Trading Halt

### Description

The securities of Invex Therapeutics Limited ('IXC') will be placed in trading halt at the request of IXC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 24 July 2020 or when the announcement is released to the market.

### Issued by

**Madeleine Green**

Senior Adviser, Listings Compliance (Perth)



Mr Sean Maloney  
Senior Adviser, Listings Compliance (Perth)  
ASX Compliance Pty Ltd  
Level 40, Central Park, 152 -158 St Georges Terrace  
PERTH WA 6000

By Email: [tradinghaltspert@asx.com.au](mailto:tradinghaltspert@asx.com.au)

22 July 2020

Dear Sean

**TRADING HALT**

Invex Therapeutics Limited (ACN 632 145 334) (**Company**) hereby requests a trading halt on its securities, effective from the commencement of trading on Wednesday, 22 July 2020, and provides the following information in relation to ASX Listing Rule 17.1:

- the Company expects to make an announcement to the market in relation to the initial scientific advice from both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) regarding its proposed development plans for Presendin™ in idiopathic intracranial hypertension ("Initial Regulatory Advice");
- the Company wishes the trading halt to last until the earlier of commencement of normal trading on Friday, 24 July 2020 and the Company making an announcement about the Initial Regulatory Advice;
- the Company is not aware of any reason why the trading halt should not be granted; and
- the Company is not aware of any other information that is necessary to inform the market about the trading halt.

If you have any queries, please do not hesitate to contact me on 0412 830 308.

Yours faithfully

Narelle Warren  
Non-executive Director/Company Secretary